The Uncle Kory Foundation looks forward to collaborating with like-minded individuals and organizations to inspire and bring hope to those who are facing such life-altering challenges. GBM accounts for approximately 17 percent of all brain tumors and increases in frequency with age, affecting more men than women. Unfortunately for all of them, the prognosis is grim, as few will live to see 3 years after diagnosis. Most patients will live only 6-18 months. The entire family is affected by the devastating news. The Uncle Kory Foundation’s mission is to advance innovative and collaborative brain cancer research to specifically improve the survival rate and treatment of those diagnosed with Glioblastoma (GBM).




international study led by researchers at UCLA and at Northwest Biotherapeutics, DCVax-L

An international Phase 3 study has found that a personalized glioblastoma vaccine may increase long-term survival in some patients. Nearly 30 percent of patients in the current trial have now survived at least three years post-enrollment, with patients continuing to be followed over time. READ MORE PRESS RELEASE

Preston Robert Tisch Brain Tumor center: Recombinant Poliovirus Therapy

From the Preston Robert Tisch Brain Tumor Center at Duke University and their Recombinant Poliovirus Therapy.  As reported in the New England Journal of Medicine in July 2018 this clinical trial has made major advancements in the treatment of recurrent glioblastomas.  As of June 2018 two participants in this study had surpassed six years of survival, one patient over five years, and many others between two and six years.  This is incredible news as the average survival rate is less than 20 months for recurrent brain tumors.  They expect even more success as they add a check point inhibitor to the study and we will report back as we learn more about this exciting advancement. READ MORE

md anderson: Smart bomb virus shows promise as brain tumor immunotherapy

A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer, researchers from The University of Texas MD Anderson Cancer Center report on a phase I clinical trial in the Journal of Clinical Oncology. READ MORE

Duke Medicine: A Guided Immunotoxin Missile for Treatment of Malignant Brain Tumors

The collaboration between Dr. Ira Pastan at the National Cancer Institute and Dr. Bigner’s team at Duke, has helped develop an immunotoxin missile that identifies two of the most important “driver-oncogene” molecules present in 95% of glioblastomas, EGFRwt and EGFRvIII.  This is the only guided immunotoxin treatment that targets both of these molecules. Previous treatments have only been able to attack cells with one of these two gene products. READ MORE

UCSD: Fluorescence Microscope Filter

It is Dr. Bob Carter’s belief that fluorescence imaging could dramatically improve surgical outcomes in patients with malignant and intrinsic brain tumors. Based on early proof of concept research, Dr. Carter believes tumors will fluoresce more brightly in the most aggressive part(s) of the tumor. If this is proven true over the coming year, then surgeons can assess the area of the tumor with the most activity and target that area in surgery with special care. This could potentially reduce, or even eliminate, the cancer spreading throughout the brain. READ MORE